金新康通过卡尔西纽林/动氨酸相关蛋白1信号通路缓解线粒体功能障碍,缓解心力衰竭
Liwen Lin1, Honglin Xu2, Zhengyang Yao1
1Guangzhou University of Chinese Medicine, Guangzhou, China.
Journal of ethnopharmacology
|August 10, 2024
概括
晋新康 (JXK) 是一种传统的中国草药配方,通过调节氨酸/动氨酸相关蛋白1 (CaN/Drp1) 途径和增强线粒体功能,改善慢性心力衰竭 (CHF) 的心脏功能.
科学领域:
- 心血管研究研究心血管研究
- 传统中国医药 传统中国医药
- 线粒体生物学 线粒体生物学
背景情况:
- 慢性心力衰竭 (CHF) 是一种衰弱的疾病,其特点是心脏功能障碍.
- 金辛康 (JXK) 是一种传统的中国草药配方,在治疗心脏不全症方面已有确定的临床疗效.
- 在CHF中JXK治疗作用的确切机制尚不清楚.
研究的目的:
- 为了研究JXK对线粒体功能的影响,在CHF的背景下.
- 阐明JXK对心脏产生治疗作用的分子机制.
主要方法:
- 使用UPLC-Q-Orbitrap-MS. 的JXK组件的定性分析.
- 在小鼠中诱导心力衰竭 (TAC模型) 和体外心脏缩 (Ang II模型).
- 评估心脏功能,线粒体参数 (Tomm20,膜潜力,ROS) 和关键蛋白质表达 (CaN,Drp1) 通过西欧 blot.
主要成果:
- 在JXK治疗改善了心脏功能,并在CHF的小鼠模型中逆转了心室重塑.
- 网络药理学和分子对接确定了氨 (CaN) 途径作为JXK活性成分的关键目标.
- JXK有效调节了CaN/Drp1通路,缓解了线粒体功能障碍在体外和体内.
结论:
- JXK治疗对慢性心力衰竭具有显著的治疗效果.
- 该机制涉及抑制CaN/Drp1通路,从而改善线粒体功能.
- JXK代表了一个有前途的治疗策略来管理CHF.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
372
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
530
相关概念视频
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
01:46Electron Transport Chain: Complex I and II
12.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.5K
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326